We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ABUS market cap is 466.68M. The company's latest EPS is USD -0.4059 and P/E is -6.38.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 5.95M | 6.25M | 6.69M | 5.01M | 4.45M |
Operating Income | -17.81M | -22.56M | -17.41M | -18.66M | -21.56M |
Net Income | -17.57M | -21.93M | -16.34M | -17.09M | -20.1M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 6.01M | 6.91M | 10.99M | 39.02M | 18.14M |
Operating Income | -144.07M | -57.33M | -73.52M | -65.46M | -78.1M |
Net Income | -153.72M | -75.87M | -88.39M | -69.46M | -72.85M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 203.8M | 195.42M | 191.22M | 176.82M | 158.64M |
Total Liabilities | 58.28M | 58.57M | 47.31M | 42.13M | 39.3M |
Total Equity | 145.52M | 136.85M | 143.92M | 134.69M | 119.34M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 105.54M | 137.08M | 204.49M | 195.42M | 144.4M |
Total Liabilities | 32.79M | 35.11M | 35.05M | 58.57M | 38.38M |
Total Equity | 72.74M | 101.97M | 169.44M | 136.85M | 106.02M |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -18.37M | -35.36M | -27.3M | -46.86M | -68.64M |
Investing | -87.62M | -74.94M | 16.68M | 18.12M | 28.55M |
Financing | 20.73M | 31.81M | 20.42M | 25.16M | 26.84M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -71.01M | -51.44M | -67.53M | -35.36M | -85.94M |
Investing | 28.34M | -14.91M | -12.68M | -74.94M | 50.77M |
Financing | 37.46M | 86.75M | 137.24M | 31.81M | 30.65M |
Market Cap | 466.68M |
Price to Earnings Ratio | -6.38 |
Price to Sales Ratio | 25.62 |
Price to Cash Ratio | 17.69 |
Price to Book Ratio | 4.38 |
Dividend Yield | - |
Shares Outstanding | 179.49M |
Average Volume (1 week) | 495.38k |
Average Volume (1 Month) | 647.01k |
52 Week Change | -15.03% |
52 Week High | 3.145 |
52 Week Low | 1.69 |
Spread (Intraday) | 0.02 (0.77%) |
Company Name | Arbutus Biopharma Corporation |
Address |
100 burnaby, british columbia V5J 5J8 |
Website | https://www.tekmirapharm.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions